Abstract / Summary
Background and objectivesPrevious studies suggest a link between tumor necrosis factor-alpha (TNF-alpha) levels and atrial fibrillation (AF). However, the nature of this relationship is disputed. To address this, we conducted a study to gather and assess evidence on the association between TNF-alpha and AF prediction.MethodologyStudies were systematically searched and collected from four databases and different types of gray literature to cover all available evidence. After the screening, the selected articles' quality and risk of bias assessment were evaluated. Meta-analysis calculated std. mean difference on the extracted data. Furthermore, heterogeneity, sensitivity, subgroups, and publication bias analyses were assessed.ResultsTwenty-three studies were included in this systematic review and meta-analysis, comprising a total of 2,369 patients with atrial fibrillation (AF) and 6,091 control participants. Pooled analysis using a random-effects model demonstrated a significant positive association between serum TNF-alpha levels and AF (standardized mean difference [SMD] = 1.15; 95% CI: 0.57-1.74; P = 0.0001). However, substantial between-study heterogeneity was observed (τ2= 1.4060; Cochran's Q = 947.52; I2= 98.82%; P < 0.0001), indicating considerable variability in effect sizes across the included studies.ConclusionsElevated TNF-α levels are significantly associated with the presence of atrial fibrillation. Despite strong overall evidence, substantial heterogeneity and publication bias were observed among studies. These findings support a role for inflammation in AF and highlight the need for more standardized future research.
Primary Source
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Ask Prognia AI
Have questions about this meta-analysis?
Prognia AI can search this source alongside 35M+ PubMed papers and current ESC, AHA, NICE, and ADA guidelines to give you a fully cited clinical answer.
Related Clinical Guidelines
Related Blog Posts
ESC 2023 Heart Failure Guidelines: What Every Cardiologist Needs to Know
The 2023 focused update to the ESC Heart Failure Guidelines introduced key changes to SGLT2 inhibitor recommendations, HFmrEF management, and device therapy thresholds. Here is a practical summary.
CHADS₂-VASc in Practice: When to Start Anticoagulation in AF
A practical walkthrough of the CHADS₂-VASc scoring system, its ESC guideline thresholds, and how to use it alongside HAS-BLED to counsel patients with atrial fibrillation.